sinc
first
use
vaccin
edward
jenner
vaccin
becam
indispens
procedur
centuri
diseas
includ
poliomyel
measl
mump
rubella
other
caus
estim
million
infect
unit
state
america
alon
vaccin
howev
render
infect
uncommon
centuri
inde
past
year
wit
tremend
advanc
develop
viral
vaccin
vaccin
reduc
global
mortal
rate
caus
infecti
diseas
approxim
three
million
peopl
per
year
inocul
variol
case
smallpox
viru
first
systemat
practic
protect
human
infecti
agent
box
procedur
becam
popular
europ
centuri
end
centuri
edward
jenner
introduc
use
cowpox
live
virus
inocul
human
protect
smallpox
procedur
call
vaccin
consid
remark
advanc
variol
centuri
way
viral
vaccin
produc
would
revolution
introduct
anim
cell
cultur
allow
vitro
propag
virus
pave
way
develop
sever
vaccin
fig
viru
attenu
inactiv
becam
standard
practic
centuri
use
form
vaccin
viral
infect
numer
attenu
vaccin
measl
polioviru
rubella
develop
use
cell
cultur
passag
box
inocul
variol
vaccin
procedur
inocul
variol
case
smallpox
first
systemat
practic
protect
human
infecti
agent
initi
live
virus
use
inocul
ie
subcutan
administr
liquid
taken
pustul
person
show
mild
symptom
healthi
person
confer
immun
protect
viral
pathogen
term
variol
refer
sole
inocul
smallpox
viru
latin
name
viru
variola
howev
inocul
attend
risk
recipi
could
develop
diseas
spread
other
addit
transmiss
diseas
via
bloodborn
rout
syphili
also
concern
end
centuri
cowpox
live
virus
variant
affect
cow
inocul
human
protect
smallpox
human
variant
procedur
call
vaccin
word
deriv
latin
vacca
mean
cow
introduct
recombin
dna
techniqu
onward
enabl
technolog
leap
vaccin
develop
use
molecular
biolog
genet
engin
provid
novel
strategi
viral
attenu
also
novel
type
vaccin
express
antigen
protein
cdna
possibl
result
product
larg
amount
highli
pure
antigen
thu
provid
dose
exampl
first
hepat
b
hbv
vaccin
manufactur
purifi
plasma
infect
patient
nowaday
recombin
hbv
vaccin
produc
cho
cell
genet
cell
line
develop
advanc
anim
cell
cultur
technolog
introduc
novel
cell
line
improv
product
bioprocess
allow
scale
suspens
cultur
provid
competit
yield
begin
centuri
wit
approv
commerci
novel
type
viral
vaccin
particl
vlp
vlp
structur
resembl
whole
viru
lack
genet
materi
exampl
market
vlp
vaccin
develop
human
papillomaviru
hpv
current
toolbox
vaccin
develop
quit
vast
deeper
comprehens
immun
system
togeth
remark
technolog
innov
led
design
myriad
differ
viral
vaccin
eg
dna
vaccin
chimer
hybrid
viral
particl
vector
vaccin
virus
antigen
obtain
dna
shuffl
differ
viral
strain
fig
despit
technolog
progress
promis
prospect
diseas
control
vaccin
sever
challeng
still
stand
mani
diseas
vaccin
avail
novel
virus
sure
emerg
avail
vaccin
may
effect
prevent
diseas
suppli
may
still
insuffici
cost
may
high
worldwid
distribut
particularli
develop
countri
instanc
tradit
manufactur
method
influenza
vaccin
abl
rapidli
respond
pandemia
use
egg
propag
viru
one
bottleneck
pose
manufactur
problem
occasion
result
distribut
delay
case
pandemia
requir
number
qualiti
fertil
egg
capac
process
unlik
match
worldwid
need
addit
grow
demand
improv
vaccin
safeti
fuel
manufactur
requir
recommend
regulatori
entiti
eg
fda
ema
antivaccin
group
inde
technolog
outdat
pose
safeti
issu
alreadi
licens
vaccin
exampl
paralysi
side
effect
observ
oral
vaccin
polioviru
dissemin
infect
bacil
bcg
vaccin
henc
older
vaccin
manufactur
process
need
inde
vaccin
continu
evolv
technolog
order
provid
safer
mean
immun
protect
patient
reduc
possibl
side
effect
newer
molecular
technolog
play
role
demand
improv
safeti
profil
vaccin
design
manufactur
process
exampl
recombin
vaccin
design
minim
elimin
virul
revers
potenti
threat
tradit
attenu
vaccin
concern
manufactur
product
purif
process
also
care
establish
level
one
particular
concern
use
choic
cell
substrat
use
viral
vaccin
product
thorough
character
cell
substrat
essenti
establish
qualiti
control
system
allow
exampl
confirm
final
product
contamin
adventiti
agent
oncogen
protein
dna
host
cell
addit
increas
effort
place
optim
anim
cell
substrat
improv
product
capac
reduc
cost
aim
worldwid
distribut
triumph
tradit
viral
vaccin
undeni
inspir
notwithstand
introduc
previous
varieti
challeng
remain
develop
novel
vaccin
obtain
effici
protect
pathogen
vaccin
yet
avail
virus
certain
emerg
ii
reduc
cost
vaccin
product
iii
establish
manufactur
platform
allow
worldwid
suppli
iv
increas
vaccin
safeti
compli
stringent
regulatori
guidelin
discuss
view
novel
molecular
biolog
tool
avail
design
new
viral
vaccin
human
use
anim
cell
substrat
manufactur
live
attenu
viral
vaccin
use
live
virus
first
type
vaccin
use
histor
live
virus
initi
use
inocul
although
inocul
procedur
still
use
veterinari
vaccin
human
use
longer
case
type
live
virus
use
human
vaccin
live
attenu
licens
vector
vaccin
clinic
develop
sever
approach
attenu
virus
one
use
procedur
involv
grow
virus
foreign
host
anim
cell
cultur
replic
poorli
sever
vaccin
develop
use
procedur
includ
polioviru
measl
rubella
vaccin
today
live
attenu
vaccin
obtain
addit
molecular
strategi
reassort
eg
influenza
rotaviru
mutat
delet
viral
gene
eg
dengu
viru
codon
deoptim
eg
polioviru
one
concern
relat
live
attenu
vaccin
possibl
revers
virul
form
seen
first
polio
oral
vaccin
context
inactiv
vaccin
provid
safer
altern
attenu
vaccin
inactiv
vaccin
gener
kill
destroy
pathogen
achiev
chemic
mean
use
exampl
formalin
formaldehyd
physic
heat
irradi
sever
inactiv
viral
vaccin
commerci
avail
exampl
influenza
rabi
polioviru
tabl
addit
present
safer
profil
compar
attenu
viral
vaccin
inactiv
vaccin
also
stabl
although
inactiv
vaccin
quit
effect
pathogen
other
induc
effect
andor
immun
sinc
give
rise
cytotox
cell
immun
respons
import
effici
fight
intracellular
pathogen
virus
multipl
dose
adjuv
often
use
subunit
vaccin
contain
part
pathogen
vaccin
use
immunodomin
antigen
specif
part
viru
full
protein
peptid
known
stimul
gener
neutral
antibodi
nab
subunit
viral
vaccin
develop
inactiv
viral
vaccin
instead
gener
antibodi
pathogen
antigen
one
antigen
use
real
challeng
develop
subunit
vaccin
identifi
antigen
induc
protect
immun
exampl
subunit
viral
vaccin
avail
hepat
b
vaccin
eg
gsk
merck
recent
approv
influenza
vaccin
protein
scienc
subunit
vaccin
hepat
b
produc
recombin
technolog
use
either
yeast
cho
cell
vaccin
recombin
trival
hemagglutinin
rha
vaccin
produc
insect
cell
cultur
use
baculoviru
express
system
similarli
inactiv
vaccin
subunit
vaccin
stabl
consid
safer
live
attenu
vaccin
main
disadvantag
lower
immun
respons
elicit
compar
live
attenu
requir
adjuv
often
multipl
dose
complex
vaccin
design
vlp
dna
vaccin
vector
vaccin
vector
vlp
vaccin
often
classifi
subunit
vaccin
sinc
provid
antigen
pathogen
either
form
protein
genet
materi
purpos
review
describ
type
vaccin
vlp
particl
structur
antigen
mimick
three
dimension
structur
pathogen
vlp
devoid
genet
materi
vlp
consid
safer
live
attenu
vaccin
vlp
subcategor
envelop
vlp
base
structur
vlp
typic
compos
one
protein
viru
particl
incorpor
host
protein
envelop
vlp
complex
structur
wrap
lipid
membran
envelop
deriv
produc
cell
target
antigen
anchor
order
repetit
structur
vlp
exhibit
excel
properti
capabl
elicit
innat
adapt
immun
respons
inde
vlp
mount
effect
immun
protect
without
use
molecul
requir
lower
dose
solubl
protein
antigen
see
review
addit
vlp
structur
favor
uptak
antigen
present
cell
apc
essenti
elicit
immun
protect
apc
display
foreign
antigen
complex
major
histocompat
complex
mhc
surfac
recogn
complex
receptor
tcr
start
immun
respons
stimul
b
lymphocyt
first
vlp
licens
human
use
human
papillomaviru
hpv
vaccin
merck
produc
yeast
tabl
hpv
approv
shortli
produc
use
baculoviru
express
system
bev
use
insect
cell
bival
hpv
vaccin
protein
indic
prevent
cervic
cancer
ema
approv
fda
approv
vlp
structur
divers
function
versatil
forecast
intensif
vlp
research
futur
develop
innov
vaccin
design
dna
vaccin
develop
bacteri
plasmid
construct
express
encod
antigen
administ
vivo
transfect
patient
cell
elicit
cellular
humor
immun
dna
vaccin
approv
veterinari
use
eg
west
vaccin
hors
salmonid
fish
yet
human
use
one
initi
bottleneck
associ
dna
vaccin
low
potenc
improv
develop
effici
deliveri
system
vivo
improv
formul
adjuv
review
dna
vaccin
see
complex
subunit
vaccin
propos
engin
modern
vaccin
base
differ
type
vector
vaccin
vlp
discuss
next
section
develop
vlp
reveal
truli
challeng
mani
virus
eg
rotaviru
hepat
c
viru
hcv
influenza
therefor
subset
vlp
contain
viral
protein
unrel
virus
known
chimer
vlp
emerg
vlp
heterolog
antigen
present
achiev
molecular
fusion
chemic
conjug
fuel
exist
alreadi
licens
hbv
vaccin
chimer
vlp
one
use
scaffold
protein
peptid
display
engraft
foreign
sequenc
hbv
capsid
protein
howev
interfer
correct
vlp
assembl
solut
maintain
vlp
integr
combin
two
differ
protein
hybrid
vlp
strong
broad
immun
respons
gener
use
hybrid
vlp
compos
protein
hpv
differ
hiv
glycoprotein
heterolog
present
glycoprotein
also
achiev
pseudotyp
envelop
vlp
envelop
protein
unrel
viru
inde
pseudotyp
retrovir
vector
wide
explor
field
gene
therapi
common
exampl
pseudotyp
vaccin
develop
use
hcv
hiv
envelop
pseudotyp
murin
leukeamia
viru
mlv
vlp
pseudotyp
also
gener
bival
vaccin
candid
glycoprotein
differ
viru
incorpor
envelop
newcastl
diseas
viru
influenza
viru
rabi
viru
ebolaviru
whole
heterolog
antigen
present
also
explor
strategi
maintain
structur
authent
target
antigen
thu
meet
qualiti
criteria
otherwis
difficult
achiev
express
isol
target
antigen
inde
express
hiv
envelop
protein
individu
hinder
natur
conform
arrang
trimer
hamper
correct
present
shown
monomer
subunit
fail
induc
broad
nab
prevent
infect
convers
hammond
et
al
demonstr
guinea
pig
model
enhanc
neutral
antibodi
respons
elicit
hiv
vlp
compar
hiv
isol
subunit
protein
vlp
also
incorpor
small
molecul
protein
refer
vector
vlp
simplic
whenev
genet
materi
incorpor
viral
particl
refer
vector
vaccin
section
vlp
vector
vaccin
also
chimer
code
display
antigen
requir
vaccin
purpos
composit
protein
virus
serv
display
scaffold
provid
gene
deliveri
function
potenti
viral
capsid
protein
encapsul
deliv
small
molecul
nucleic
acid
protein
larg
explor
drug
develop
gene
therapi
compani
mediat
cargo
deliveri
specif
cell
tissu
organ
cell
tissu
specif
achiev
use
viral
envelop
protein
embed
antibodi
cellular
receptor
vaccin
develop
translat
strategi
new
class
vaccin
known
vector
vlp
vaccin
encapsid
small
molecul
like
doxorubicin
assembl
vlp
potenti
activ
vaccin
full
protein
peptid
fuse
capsid
protein
without
cleavabl
linker
releas
upon
cell
entri
appli
solubl
protein
specif
antigen
epitop
deliv
peptid
deliv
function
immunomodulatori
protein
transcript
factor
cytokin
tlr
ligand
adjuv
vlp
surfac
modif
use
sever
purpos
polym
polyethylenimin
act
adjuv
polyethylen
glycol
peg
increas
vlp
stabil
addit
vlp
cover
immunostimulatori
agent
exampl
rabbit
hemorrhag
fever
vlp
cover
glycolipid
show
enhanc
immunogen
compar
vlp
challeng
achiev
effici
transfect
dna
vaccin
led
develop
vector
vaccin
vector
vaccin
herein
defin
vehicl
carri
gene
virus
purpos
express
host
cell
elicit
immun
protect
respons
vector
vaccin
like
dna
vaccin
potenti
elicit
b
cell
immun
howev
sinc
vector
vaccin
requir
live
virus
vaccin
less
stabl
plasmid
dna
vaccin
difficult
manufactur
sever
vaccin
vector
code
viral
gene
immunodefici
viru
yellow
fever
viru
human
cytomegaloviru
test
experiment
candid
vaccin
tabl
dna
rna
explor
cargo
gene
deliveri
virus
harbor
dna
rna
genom
therefor
sever
strategi
transport
nucleic
acid
explor
vaccin
deliv
nucleic
acid
often
aim
promot
transient
express
cargo
encod
protein
immunostimulatori
properti
immunogen
often
encod
promot
antigen
present
via
nevertheless
nucleic
acid
also
induc
express
immunomodulatori
protein
block
immunosupressor
pathway
deliveri
small
interf
rna
sirna
concept
vector
vaccin
extens
explor
ideal
vector
vaccin
human
use
virus
abl
deliv
antigen
target
cell
form
genet
materi
nevertheless
replic
compet
vector
vaccin
develop
veterinari
use
myriad
viral
vector
avail
base
adenoviru
poxviru
herp
simplex
viru
cytomegaloviru
alphavirus
viru
adenovirus
perhap
use
vaccin
vector
adenovirus
easili
produc
human
embryon
kidney
hek
cell
high
titer
express
transgen
high
level
activ
innat
immun
system
stimul
dendrit
cell
matur
sever
candid
vaccin
hiv
use
adenoviru
adenoviru
type
vaccin
express
individu
antigen
hiv
envelop
protein
gag
shown
induc
cell
respons
clinic
studi
merck
evalu
recombin
adenoviru
type
vector
express
clade
b
gag
pol
nef
individu
termin
howev
unsuccess
yet
anoth
clinic
trial
provid
first
signal
hiv
vaccin
efficaci
latter
recombin
canarypox
vector
vaccin
evalu
prime
envelop
protein
boost
regimen
demonstr
protect
effect
acquisit
hiv
infect
subject
ongo
effort
develop
next
gener
recombin
adenoviru
vaccin
hiv
includ
develop
altern
serotyp
adenovir
vector
incorpor
adenovir
vector
heterolog
vector
regimen
use
adenovir
vector
express
novel
hiv
antigen
improv
immunolog
coverag
circul
virus
new
concept
also
emerg
vivo
express
vlp
plasmovlp
use
dna
vaccin
technolog
plasmovlp
combin
dna
vlp
type
vaccin
one
given
complementari
potenti
dna
vlp
vaccin
bellier
colleagu
design
singl
vector
form
would
endow
respect
advantag
properti
plasmid
administ
dna
vaccin
express
compon
need
vlp
format
retrovlp
base
murin
leukemia
viru
mlv
combin
straightforward
stabil
product
dna
vaccin
immunostimulatori
properti
vlp
vaccin
circumv
labori
vlp
vaccin
product
purif
formul
process
technolog
shown
produc
correctli
fold
assembl
vlp
vivo
mice
macaqu
induc
earlier
significantli
higher
level
nab
simpli
express
viral
envelop
protein
plasmid
dna
also
circul
nab
maintain
longer
period
time
could
boost
addit
deliveri
later
studi
use
anim
model
show
abl
prime
apc
gener
protect
immun
respons
hcv
hiv
appear
promis
strategi
treatment
cancer
hybrid
design
vaccin
case
vector
vaccin
combin
vector
vlp
ie
display
antigen
form
protein
combin
deliveri
antigen
form
genet
materi
either
dna
rna
case
alphavirus
flavivirus
produc
without
portion
genom
modifi
code
foreign
viral
antigen
interest
use
immun
vlp
one
replic
cycl
type
vaccin
still
develop
phase
hold
great
potenti
anoth
current
interest
develop
univers
viral
vaccin
would
great
interest
highli
divers
virus
influenza
univers
flu
vaccin
could
provid
protect
regardless
strain
subtyp
circul
viru
allow
vaccin
prepar
advanc
readi
use
event
pandem
would
also
sever
advantag
current
avail
season
vaccin
requir
less
frequent
administr
ideal
one
develop
univers
vaccin
reli
util
highli
conserv
antigen
target
main
difficulti
lie
access
conserv
antigen
epitop
sinc
usual
less
expos
gener
weak
immunogen
therefor
univers
vaccin
immunogen
identifi
conserv
antigen
increas
induc
protect
immun
case
influenza
viru
sever
promis
candid
antigen
propos
includ
hemagglutinin
ha
matrix
protein
nucleoprotein
neuraminidas
na
protein
extens
revis
see
strategi
find
conserv
antigen
target
confin
influenza
viru
concept
interest
also
highli
variabl
virus
hiv
hcv
research
effort
find
conserv
immunogen
epitop
hiv
exhaust
envelop
glycoprotein
one
primari
target
larg
expos
virion
surfac
antibodi
respons
hiv
infect
individu
great
extent
direct
variabl
extens
glycosyl
howev
pose
difficulti
patient
gener
broad
neutral
respons
larg
number
broadli
neutral
antibodi
bnab
hiv
discov
last
decad
four
major
epitop
env
surfac
target
bnab
exist
indic
possibl
elicit
neutral
respons
develop
effect
vaccin
review
sever
strategi
ongo
see
similarli
hiv
divers
hcv
viru
also
pose
major
challeng
vaccin
develop
yet
broadli
monoclon
antibodi
direct
envelop
glycoprotein
effici
block
hcv
infect
variou
genotyp
recent
isol
infect
patient
immun
anim
studi
also
identifi
essenti
conserv
epitop
may
use
vaccin
design
thu
renew
hope
develop
steril
vaccin
hcv
major
challeng
hamper
faster
progress
develop
hcv
vaccin
still
present
inexist
suitabl
anim
model
abl
reproduc
stage
infect
immun
respons
found
human
chimpanze
summari
vaccin
strategi
aim
deliv
conserv
immunogen
antigen
gener
develop
sever
vaccin
type
recombin
protein
vlp
vector
vaccin
other
advantag
disadvantag
describ
section
common
viral
vaccin
tradit
recombin
need
cell
substrat
biolog
factori
enabl
product
vaccin
next
section
revisit
histori
cell
substrat
use
viral
vaccin
manufactur
recent
develop
anim
cell
cultur
develop
engin
leverag
product
tradit
modern
vaccin
edward
jenner
demonstr
protect
effect
cowpox
smallpox
infect
use
matter
fresh
cowpox
lesion
milkmaid
direct
immun
healthi
eight
boy
human
skin
thu
consid
first
cell
substrat
viral
vaccin
manufactur
late
cell
cultur
first
use
john
ender
thoma
weller
frederick
robbin
abl
propag
polioviru
tissu
name
human
embryon
skin
muscl
tissu
breakthrough
would
grant
nobel
prize
physiolog
medicin
tissu
primari
cultur
privileg
cell
substrat
choic
product
viral
vaccin
diploid
cell
line
cell
strain
deriv
lung
tissu
also
use
grow
viru
product
rubella
vaccin
cell
vaccin
polioviru
hepat
viru
rabi
viru
varicella
viru
cell
rotaviru
rabi
vaccin
last
decad
centuri
wit
use
first
continu
cell
line
vero
deriv
kidney
african
green
monkey
manufactur
inactiv
poliomyel
vaccin
ipv
later
oral
poliomyel
vaccin
opv
approv
vero
cell
line
vaccin
manufactur
landmark
open
import
preced
use
cell
substrat
initi
transit
cell
strain
cell
line
also
year
use
tumorigen
cell
line
product
vaccin
emerg
viral
pathogen
start
discuss
begin
centuri
first
tumorigen
cell
line
introduc
product
live
viral
vaccin
proprietari
cell
line
crucel
design
product
adenoviru
vector
hiv
vaccin
also
first
exampl
substrat
shortli
madin
darbi
canin
kidney
mdck
cell
line
propos
product
inactiv
influenza
viru
vaccin
mdck
cell
line
isol
kidney
appar
normal
dog
spontan
immort
variant
mdck
cell
describ
highli
tumorigen
other
ema
approv
fda
approv
first
human
flu
vaccin
produc
use
mdck
cell
line
put
novarti
pioneer
compani
transit
mammalian
product
influenza
vaccin
first
decad
centuri
also
wit
approv
insect
cell
line
bev
platform
product
human
viral
vaccin
gsk
bev
system
gain
attent
first
recombin
vaccin
flu
sole
base
protein
protein
scienc
approv
end
use
cell
line
deriv
human
tumor
start
consid
vaccin
manufactur
vaccin
relat
biolog
product
advisori
committe
vrbpac
recogn
current
repertoir
cell
substrat
inadequ
manufactur
certain
type
new
vaccin
cell
line
deriv
tumor
may
optim
case
cell
substrat
use
propag
certain
vaccin
virus
one
major
challeng
anim
cell
cultur
immort
establish
continu
cell
line
spontan
immort
rare
event
human
cell
promot
oncogen
soon
observ
virus
abil
induc
immort
viral
gene
genom
thu
use
immort
cell
classic
exampl
hek
cell
establish
earli
transform
cultur
normal
human
embryon
kidney
cell
shear
adenoviru
dna
current
sever
immort
viral
gene
sequenc
identifi
eg
adenoviru
gene
simian
viru
larg
antigen
hpv
gene
viru
lmp
ebna
gene
human
leukemia
viru
sequenc
tax
cellular
oncogen
mutant
gene
also
immort
cell
hek
cell
wide
use
propag
vector
vaccin
base
adenoviru
lack
gene
genom
major
issu
use
hek
cell
adenovir
vector
vaccin
product
format
replic
compet
adenoviru
rca
recombin
viru
genom
adenoviru
dna
use
process
immort
hek
transcompl
design
cell
line
appear
respond
need
safer
cell
line
hek
tabl
overal
strategi
base
reduc
sequenc
cell
immort
led
develop
cell
line
human
embryon
retinoblast
cell
transform
sequenc
compris
encod
sequenc
addit
control
human
pgk
promot
compens
remov
endogen
promot
year
later
design
cell
line
hela
cell
human
aminocyt
establish
reduc
sequenc
homolog
immort
dna
integr
cell
genom
vector
vaccin
viral
genom
reduc
possibl
doubl
homolog
recombin
gener
rca
cell
deriv
human
aminocyt
proprietari
cell
line
cevec
detail
histori
cell
line
review
cell
line
alreadi
test
proven
suitabl
propag
virus
adenoviru
includ
influenza
cell
line
develop
compris
genet
manipul
perform
even
gene
stabli
express
directli
relat
viru
produc
case
probiogen
cell
line
develop
obviat
depend
primari
chicken
embryo
fibroblast
cef
product
modifi
vaccinia
ankara
viru
mva
cell
line
deriv
muscovi
duck
retina
cr
somit
cs
amnion
membran
ca
cell
immort
gene
human
tabl
interestingli
ca
cell
report
refractori
mva
replic
wherea
evid
differ
phenotyp
observ
cr
cs
cell
cr
cell
cultiv
without
anchorag
wherea
cs
cell
prolifer
monolay
output
highlight
import
cell
background
properti
final
cell
line
relev
establish
robust
vaccin
product
process
cell
line
also
alreadi
subject
cell
line
engin
see
section
anoth
type
cell
line
develop
concern
constitut
express
viral
compon
stabl
product
vaccin
base
viral
protein
viral
particl
eg
vlp
exampl
type
cell
line
develop
establish
product
hbv
vaccin
tabl
cell
line
develop
stabl
product
vlp
use
viral
protein
cytotox
two
recent
exampl
cell
develop
product
rabi
vlp
cell
product
japanes
enceph
viru
vlp
tabl
protein
cytotox
transient
approach
use
instead
stabl
product
vlp
anim
cell
face
difficult
competit
impress
yield
obtain
bev
system
howev
bev
system
may
pose
particularli
challeng
downstream
process
difficulti
sinc
separ
vaccin
product
baculoviru
contamin
may
complic
case
vlp
envelop
stabl
insect
cell
line
system
base
recombinas
mediat
cassett
exchang
develop
anoth
exampl
still
context
stabl
insect
cell
line
report
stabl
doubl
transfect
hiv
gag
product
envelop
vlp
present
trimer
surfac
group
engin
baculoviru
order
make
thu
reduc
baculoviru
contamin
minim
level
cell
line
engin
compris
genet
manipul
improv
product
perform
cell
line
mostli
exclus
increas
titer
fig
report
cell
line
engin
viral
vaccin
manufactur
rel
scarc
fact
gene
engin
anim
cell
labor
intens
may
perceiv
cell
line
alreadi
support
vaccin
product
still
tabl
show
sever
effort
cell
line
engin
viral
vaccin
manufactur
made
particularli
last
five
year
highlight
increas
interest
field
one
first
studi
cell
line
engin
report
chu
et
al
transcriptom
base
studi
compar
hela
cell
identifi
one
gene
play
role
control
cell
adhes
chosen
express
mdck
cell
line
cell
line
lost
anchorag
depend
phenotyp
produc
time
higher
ha
titer
parent
mdck
cell
mdck
cell
line
also
subject
genet
engin
intracellular
innat
defens
specif
interferon
regulatori
factor
increas
influenza
titer
author
could
link
inhibit
titer
increas
suggest
rna
interfer
mediat
knockdown
mdck
cell
enhanc
viru
propag
unknown
mechan
previous
mention
cell
line
develop
subject
cell
line
engin
stabl
express
structur
gene
pix
human
adenoviru
increas
titer
poxviru
main
viral
product
manufactur
cell
tabl
author
suggest
improv
viral
titer
mediat
via
induct
heat
shock
pathway
recent
overexpress
human
scaveng
receptor
class
b
member
report
improv
product
human
enteroviru
type
coxsackieviru
group
type
hek
human
rhabdomyosarcoma
rd
vero
cell
line
inde
previous
identifi
one
receptor
suggest
overexpress
could
potenti
gene
engin
approach
increas
suscept
express
cell
virus
cell
line
engin
also
use
provid
specif
featur
viral
particl
exampl
group
use
stabl
express
mediat
rna
interfer
knockdown
express
hek
deriv
cell
line
stabli
produc
retrovlp
tabl
cell
line
current
use
product
chimer
hcv
vaccin
candid
consist
hcv
glycoprotein
anchor
retrovir
core
vlp
particl
assembl
cellular
membran
natur
incorpor
sever
host
cell
protein
includ
larg
extent
later
elicit
unwant
humor
immun
respons
retrovlp
hamper
effect
immun
respons
hcv
candid
vaccin
field
cell
line
engin
wit
signific
invest
focus
improv
product
recombin
protein
mainli
monoclon
antibodi
sever
pathway
target
includ
apoptosi
protein
secretori
pathway
glycosyl
glycolysi
leverag
grow
knowledg
interact
intensif
cell
engin
vaccin
product
also
expect
review
cell
line
engin
manufactur
vaccin
viral
vector
found
rodrigu
et
al
replac
cell
line
alreadi
market
vaccin
requir
substanti
invest
henc
come
chang
new
cell
substrat
manufactur
industri
tend
conserv
howev
resist
start
break
shortag
vaccin
suppli
one
drive
forc
instanc
novarti
alreadi
use
mdck
product
although
maintain
product
oldest
version
use
tradit
embryon
egg
manufactur
process
new
design
old
vaccin
also
pursu
protein
scienc
use
insect
cell
product
exclus
base
protein
ha
first
vaccin
season
flu
avoid
use
influenza
viru
introduct
novel
vaccin
design
cell
line
face
less
resist
case
diseas
vaccin
treatment
avail
particularli
life
threaten
sever
debilit
one
hand
global
acceler
spread
mani
diseas
contain
certain
area
countri
hand
certain
virus
mechan
immun
evas
tradit
vaccin
longer
offer
solut
push
invest
scientif
medic
commun
flexibl
explor
advanc
solut
addit
avail
scientif
knowledg
technolog
develop
tremend
expect
continu
grow
almost
exponenti
offer
extens
toolbox
materi
novel
ambiti
creativ
idea
vaccin
design
thu
come
viral
vaccin
design
cell
line
develop
engin
certain
enter
whole
new
era
modern
vaccinolog
ana
sofia
coroadinha
degre
biochemistri
phd
chemic
engin
receiv
instituto
de
tecnologia
e
universidad
nova
de
lisboa
sinc
juli
head
cell
line
develop
molecular
biotechnolog
lab
anim
cell
technolog
unit
ibet
portugalh
current
research
interest
focu
manufactur
viral
vector
vaccin
use
anim
cell
compris
develop
cell
substrat
engin
recombin
viru
viral
particl
develop
enabl
tool
viru
verlag
gmbh
co
kgaa
weinheimthi
articl
made
freeli
avail
pubm
central
part
public
health
emerg
respons
use
unrestrict
research
reus
analysi
form
mean
acknowledg
origin
sourc
durat
public
health
emerg
